Gynecologic Oncology in India: Complete Guide to Women's Cancer Treatment, Diagnosis, and Expert Gynecologic Cancer Care

TL;DR: Treatment for cervical, ovarian, and uterine cancers in India costs USD 8,000–25,000 depending on stage and modality — 65–75% below USA rates. India's gynaecologic oncologists perform radical hysterectomy, cytoreductive surgery, and HIPEC (heated intraperitoneal chemotherapy). Robotic gynaecologic oncology is available at Apollo, Tata Memorial, and Fortis. (JCI, 2024)

Cervical cancer kills more than 340,000 women worldwide every year, and over 90% of those deaths occur in low- and middle-income countries — predominantly in sub-Saharan Africa and South Asia. (WHO Global Cancer Observatory, 2022). India's gynaecologic oncology centres offer a practical route to diagnosis, staging, surgery, and chemotherapy at costs most African families can manage, without sacrificing clinical standards. This guide explains what to expect.

Understanding Gynaecologic Oncology

What is Gynaecologic Oncology?

Gynaecologic oncology is the medical specialty focused on cancers of the female reproductive system. Specialists hold an MBBS, an MD in Obstetrics and Gynaecology, and a DM or equivalent fellowship in gynaecologic oncology — typically 3–5 additional years of training. They are skilled in surgery, chemotherapy, and targeted therapy, managing the full spectrum from pre-cancerous lesions to advanced metastatic disease.

Scope of Gynaecologic Oncology

Modern gynaecologic oncology covers cervical cancer, ovarian and fallopian tube cancer, endometrial cancer, vaginal cancer, vulvar cancer, uterine sarcoma, and gestational trophoblastic disease. Treatment combines surgery, chemotherapy, radiation, targeted therapy, immunotherapy, and palliative care — often all within the same hospital.

Common Gynecologic Cancers Treated

CERVICAL CANCER:

• Squamous cell carcinoma (75–80%)
• Adenocarcinoma (20–25%)
• Rare variants: small cell, neuroendocrine, clear cell

OVARIAN CANCER:

• Epithelial ovarian cancer (85–90%) including serous, mucinous, and endometrioid types
• Germ cell tumors and sex cord-stromal tumors
• Fallopian tube cancer

ENDOMETRIAL (UTERINE) CANCER:

• Adenocarcinoma (95%)
• Serous carcinoma and clear cell carcinoma
• Uterine papillary serous carcinoma (UPSC)

UTERINE SARCOMA:

• Leiomyosarcoma, endometrial stromal sarcoma, carcinosarcoma

VAGINAL AND VULVAR CANCER:

• Squamous cell carcinoma, melanoma, adenocarcinoma

GESTATIONAL TROPHOBLASTIC DISEASE:

• Hydatidiform mole, choriocarcinoma, placental site trophoblastic tumor

Why Choose Gynaecologic Oncology in India?

What Does Gynaecologic Oncology Cost in India?

Women's cancer treatment in India costs 65–75% less than in the USA or UK, while outcomes match international standards at JCI-accredited centres. (Medical Tourism Association, 2023). A complete cervical cancer treatment course — surgery, chemotherapy, and radiation — costs USD 6,500–24,000 in India versus USD 60,000–120,000 in the USA.

Citation capsule: Cervical cancer treatment in India costs USD 6,500–24,000 for surgery plus chemoradiation — versus USD 60,000–120,000 in the United States, according to the Medical Tourism Association (2023). India's Tata Memorial Hospital, Apollo, and Fortis report 5-year overall survival rates for early-stage cervical cancer of 80–95%, consistent with NCCN guideline-based outcomes.

Cost Comparison:

Service	USA	UK	India
Initial consultation + staging	$3,500–9,000	£1,200–2,400	$300–900
Radical hysterectomy	$20,000–40,000	£15,000–25,000	$3,000–8,000
Chemotherapy per cycle	$4,000–12,000	£2,000–5,000	$500–2,000
Radiation therapy course	$15,000–30,000	£8,000–15,000	$2,000–8,000

World-Class Gynaecologic Oncology Centres

India's leading centres feature:

Advanced Imaging:

• High-field MRI (3T), advanced CT, PET-CT
• Transvaginal ultrasound and image-guided biopsy
• 3D reconstruction for surgical planning

Surgical Equipment:

• Laparoscopic and robotic platforms (da Vinci)
• Sentinel lymph node mapping
• HIPEC (heated intraperitoneal chemotherapy) capability
• Pelvic lymph node dissection and bowel reconstruction expertise

Laboratory Facilities:

• Tumour marker assays (CA-125, HE4, CEA, AFP, hCG)
• HPV testing and genotyping
• Molecular genetics and BRCA testing
• Immunohistochemistry and digital pathology

Facility Standards: JCI accreditation, NABH certification, multidisciplinary tumour boards meeting weekly.

Expert Gynaecologic Oncologists

India's specialists hold 15–30 years of clinical experience, have managed thousands of gynaecologic cancer cases, and carry active memberships in international societies. Many trained at centres in the USA, UK, or Europe before returning to India.

Comprehensive Gynaecologic Oncology Services

Diagnosis and Staging

Initial Evaluation:

• Detailed history and pelvic examination
• Symptom and bleeding assessment
• Risk factor identification and performance status evaluation

Diagnostic Testing:

• Pap smear with liquid-based cytology, HPV testing
• Endometrial biopsy, colposcopy, hysteroscopy
• Punch biopsy of vulvar or vaginal lesions
• Tissue pathology with immunohistochemistry review

Tumour Markers: CA-125, HE4, CEA, AFP, hCG — selected based on cancer type.

Imaging Studies: Transvaginal ultrasound, CT chest/abdomen/pelvis, high-resolution MRI pelvis, PET-CT for advanced staging.

Cancer Type-Specific Management

Cervical Cancer:

• HPV assessment and FIGO staging
• Radical hysterectomy with pelvic lymph node dissection
• Trachelectomy (cervical preservation) for young women wanting fertility
• Concurrent chemoradiation for locally advanced disease
• Brachytherapy planning

Ovarian Cancer:

• Complete staging and cytoreduction surgery (goal: no residual disease)
• Interval debulking if primary cytoreduction not feasible
• BRCA testing and genetic counselling
• Platinum-taxane chemotherapy as first-line treatment
• PARP inhibitors for BRCA-mutated disease

Endometrial Cancer:

• Total hysterectomy and bilateral salpingo-oophorectomy
• Sentinel lymph node mapping
• Molecular classification to guide adjuvant therapy
• Radiation or chemotherapy for high-risk cases

Uterine Sarcoma: En bloc resection, aggressive staging, close surveillance, multimodal treatment.

Vaginal and Vulvar Cancer: Wide local excision, inguinal lymph node dissection, radiation and chemotherapy planning, reconstruction if needed.

Surgical Oncology

Cervical Cancer Surgery:

• Radical hysterectomy (Wertheim-Meigs procedure)
• Laparoscopic, robotic, or open approach
• Parametrial and upper vaginal resection
• Pelvic lymph node dissection

Ovarian Cancer Surgery:

• Complete staging, optimal cytoreduction (goal residual 0 cm)
• Bowel, upper abdominal, and omental assessment
• HIPEC for selected patients with peritoneal disease

Endometrial Cancer Surgery:

• Robotic or laparoscopic hysterectomy (most cases)
• Sentinel lymph node identification (ICG fluorescence)
• Para-aortic nodal assessment for high-risk histology

Chemotherapy Management

Regimens include platinum-based combinations (carboplatin, cisplatin), taxanes (paclitaxel, docetaxel), and 5-fluorouracil for cervical cancer. Chemotherapy is administered in dedicated infusion centres with full antiemetic and growth factor support. Cost per cycle: USD 500–2,000.

Targeted Therapy and Immunotherapy

• PARP inhibitors (olaparib, rucaparib) for BRCA-mutated ovarian cancer
• Bevacizumab (anti-VEGF) for ovarian and cervical cancer
• Pembrolizumab and nivolumab for advanced or recurrent disease
• Hormone receptor blockade for endometrial cancer
• Molecular profiling guides all treatment decisions

Radiation Oncology

• External beam radiation therapy (EBRT) using IMRT technique
• Intracavitary brachytherapy for cervical cancer (gold standard)
• Image-guided radiation therapy (IGRT)
• 3D conformal planning with computerised optimisation

Clinical Outcomes

Cervical Cancer Outcomes

Early-Stage Disease (Stage I–II):

• 5-year overall survival: 80–95%
• With combined chemoradiation: 80–95%
• Recurrence rate: 5–15%

Advanced Disease (Stage III–IV):

• 5-year overall survival: 50–70%
• Pelvic control with chemoradiation: 70–80%

Ovarian Cancer Outcomes

Early-Stage Disease (Stage I–II):

• 5-year overall survival: 85–95%
• Recurrence rate: 5–15%

Advanced Disease (Stage III–IV):

• 5-year overall survival: 30–50%
• Optimal cytoreduction (residual 0 cm) significantly improves survival

Endometrial Cancer Outcomes

Early-Stage (Stage I):

• 5-year overall survival: 80–95%
• Excellent prognosis with surgery alone in low-risk cases

Advanced Disease (Stage III–IV):

• 5-year overall survival: 50–70%

Uterine Sarcoma Outcomes

• Leiomyosarcoma: 5-year survival 30–50%
• Endometrial stromal sarcoma: 5-year survival 60–70%

Advanced Technologies

Robotic Surgery: Minimally invasive gynaecologic oncology with reduced blood loss, faster recovery, and enhanced precision for complex pelvic cases.

Molecular Testing: BRCA mutation testing, MSI/MMR testing, PTEN and TP53 analysis, gene expression profiling — all guiding treatment selection.

Advanced Pathology: Immunohistochemistry, FISH, digital pathology with rapid turnaround.